Zimmer's NexGen Knees Help Lift Second-Quarter Revenues 13% To $294 Mil.
This article was originally published in The Gray Sheet
Executive Summary
A 28% jump in U.S. sales of knee implants and a 26% increase in domestic artificial hip revenues helped propel Zimmer Holdings's second-quarter corporate revenues ahead 13% to $294.3 mil., the firm reported July 25.
You may also be interested in...
Zimmer
Bristol-Myers Squibb orthopedics spin-off commences independent public trading Aug. 7 on the New York Stock Exchange under the symbol "ZMH" (1"The Gray Sheet" July 30, 2001, p. 10)
Zimmer
Bristol-Myers Squibb orthopedics spin-off commences independent public trading Aug. 7 on the New York Stock Exchange under the symbol "ZMH" (1"The Gray Sheet" July 30, 2001, p. 10)
Digital Mammography Firms May Meet FDA Requirements Through NCI Trial
FDA's recommendation for post-approval studies of digital mammography devices could be moot for devices that are included in the National Cancer Institute-sponsored study scheduled to begin this June, agency officials say.